**Title Page**

**Title**

**PULSE-I - Is rePetitive Upper Limb SEnsory stimulation early after stroke feasible and acceptable? A stratified single-blinded randomised controlled feasibility study.**

**Authors:**

**Kausik Chatterjee,**

**Countess of Chester Hospital Foundation Trust, Liverpool Rd, Chester CH2 1UL**

**E-mail:** **kausikchatterjee@nhs.net**

**Rachel C Stockley,**

**Stroke Team, School of Nursing, University of Central Lancashire, Preston, UK PR1 2HE**

**E-mail:** **RStockley1@uclan.ac.uk**

**Steven Lane,**

**Department of Biostatistics, University of Liverpool, Liverpool L69 3GL**

**E-mail:** **slane@liverpool.ac.uk**

**Caroline Watkins,**

**Stroke Team, School of Nursing, University of Central Lancashire, Preston, UK PR1 2HE**

**E-mail: Caroline** **CLWatkins@uclan.ac.uk**

**Katy Cottrell,**

**Countess of Chester Hospital Foundation Trust, Liverpool Rd, Chester CH2 1UL**

**E-mail:** **katy.cottrell@nhs.net**

**Brenda Ankers,**

**Countess of Chester Hospital Foundation Trust, Liverpool Rd, Chester CH2 1UL**

**E-mail:** **brendaankers@nhs.net**

**Sioned Davies,**

**Countess of Chester Hospital Foundation Trust, Liverpool Rd, Chester CH2 1UL**

**E-mail:** **sioned.davies@nhs.net**

**Mary Fisher Morris,**

**MemCheck Memory Clinic, Beehive Healthcare, Northgate Avenue, Chester CH2 2DX**

**E-mail:** **mary.fishermorris@gmail.com**

**Nick Fallon,**

**Department of Psychological Sciences, University of Liverpool, UK L697ZA**

**E-mail:** **N.B.Fallon@liverpool.ac.uk**

**Turo Nurmikko.**

**Neuroscience Research Centre, The Walton Centre NHS Foundation Trust, Liverpool L9 7LJ**

**E-mail:** **tjn@liverpool.ac.uk**

**Corresponding author: Kausik Chatterjee**

**Abstract**

**Background**

Reduction in sensorimotor function of the upper limb is a common and persistent impairment after stroke, and less than half of stroke survivors recover even basic function of the upper limb after a year. Previous work in stroke has shown that repetitive sensory stimulation (RSS) of the upper limb may benefit motor function. As yet, there have been no investigations of RSS in the early-acute period despite this being the time window during which the neuroplastic processes underpinning sensorimotor recovery are likely to occur.

**Methods**

A single-blinded stratified randomised controlled feasibility study was undertaken at 2 NHS acute trusts to determine the recruitment rate, intervention adherence, and safety and acceptability of an RSS intervention in the early after stroke. Participants were recruited within two weeks of index stroke. Stratified on arm function, they were randomised to receive either 45 minutes of daily RSS and usual care or usual care alone (UC) for two weeks. Changes from baseline on the primary outcome of the Action Research Arm Test (ARAT) to measurements taken by a blinded assessor were examined after completion of the intervention (2 weeks) and at 3 months from randomisation.

**Results**

Forty patients were recruited and randomised (RSS: n=23; UC: n=17) with a recruitment rate of 9.5% (40/417) of patients admitted with a stroke of which 52 (12.5%) were potentially eligible, with 10 declining to participate for various reasons. Participants found the RSS intervention acceptable and adherence was good. The intervention was safe and there were no serious adverse events. Changes on the ARAT indicated successful outcome for 16 (70%) people in the RSS group and 8 (47%) in the UC group at 2 weeks; and 17(74%) in RSS and 11 (69%) in UC groups at 3 months.

**Conclusions**

This study indicates that recruitment to a trial of RSS in the acute period after stroke is feasible. The intervention was well tolerated and appeared to provide additional benefit to usual care. In addition to a definitive trial of efficacy, further work is warranted to examine the effects of varying doses of RSS upon arm function and the mechanism by which RSS induces sensorimotor recovery in the acute period after stroke.

**Trial registration:** This study was registered with ISRCTN in January 2017 (**ISRCTN registry no: ISRCTN17422343;** IRAS Project ID: 215137).

Keywords: Stroke, Upper Limb rehabilitation, Repetitive Sensory Stimulation

**Background**

Over 15 million people experience a stroke each year worldwide and, in high-income countries, stroke is the single main cause of acquired disability.[1] There are more than 1.2 million stroke survivors living in the UK with over 100,000 new cases of stroke each year.[2].

Advances in the acute care have dramatically reduced stroke mortality [3] but recovery of sensorimotor function of the upper limb remains problematic. Whilst two-thirds of stroke survivors go on to walk independently, less than 20% recover full upper limb function and over half do not regain basic functions of the upper limb after several years. [4, 5]

Completing even simple Activities of Daily Living (ADLs) often requires a substantial level of upper limb ability and so persistent impairments in upper limb function produce negative effects upon daily functioning and significantly reduce independence.[6, 7] Consequently, improving upper limb function is a core element of stroke rehabilitation.[8] Current treatment guidelines emphasize that rehabilitation should include high numbers of repetitions of motor tasks (repetitive task training, RTT) to improve sensorimotor function after stroke.[9] Recent work has also identified a five-week critical window after stroke in which most of the neuroplasticity that underpins recovery of sensorimotor control of the upper limb occurs.[10] This period presents a short but sensitive phase of increased responsiveness to rehabilitation after stroke. It also indicates that the intensity of training is likely to be key in this 5 week period to maximise neuroplastic processes and optimise the recovery of the upper limb. However, in practice, delivering high intensity RTT in the acute and early subacute period after stroke is challenging. Difficulties arise as it requires participants to be consistently and highly motivated, and rehabilitation staff need to have the time and resources to support RTT.[11, 12]

Consequently, there is a clear and urgent need to develop and evaluate new treatments. Such treatments need to be delivered in the early, sensitive period after stroke, must not require significant increases in staff time, cannot be reliant on consistently high levels of motivation in people after stroke, and able to be used by people with severe hemiparesis.

Repetitive sensory stimulation (RSS) is a largely passive treatment which has been recognized in healthy people to produce neuroplastic changes, similar to those elicited by repetitive task training.[13] These include lasting changes in corticospinal excitability which may be elicited via a GABA-ergic disinhibition and long-term potentiation produced by glutaminergic mechanisms [14].

RSS interventions have predominantly been evaluated in studies of people many months or even years after stroke [15-19] with benefits to sensation, arm and hand function. Recently, a small randomised, sham-controlled trial evaluating a 2 week RSS intervention in people commenced in the early subacute stage[20] (at least 3 or 4 weeks) after stroke showed significant benefits to sensorimotor function including tactile discrimination and global hand function.[21] However, no studies have used RSS in the acute/very early subacute period (first few days or weeks) after stroke, despite this being likely to be the optimal period for recovery of sensorimotor function.[10] However, there may be practical factors which influence the feasibility and acceptability of using the RSS in the first few days after stroke and of recruiting to and conducting a trial of its effectiveness during this period. Therefore, a study was conducted to determine: the feasibility and acceptability of using RSS in the first 2 weeks after stroke (acute and early subacute period)[20] ~~and potential changes in arm function after using RSS in the early acute period after stroke~~. Collectively this information will inform a future adequately sized randomised controlled clinical trial of RSS early after stroke.

**Methods**

**Study design**

The study was designed as a single-blind stratified randomised controlled trial, designed and funded to recruit and follow up 40 patients within one and half year. Patients were recruited at Stroke units at the Countess of Chester Hospital NHS Foundation Trust between January and November 2017 and at Basildon and Thurrock University Hospitals NHS Foundation Trust from September to November 2017. Ethical approval was obtained from North West-Liverpool Central Research Ethics Committee (ref no: 16/NW/07/71). The recruitment was stopped as it enrolled the required number of patients.

**Participants**

Participants were included if they were over 18 and had suffered a unilateral, confirmed stroke in the past 2 days to 2 weeks, which had left them with sensorimotor deficits of their arm. Those who did not have a National Institute of Health Stroke Scale (NIHSS) arm motor score between 1 and 4 (NIHSS arm score ranges from 0: no weakness to 4: no movement) and/or a pre-stroke modified Rankin scale score (mRS) between 0 and 3 were not included [22-24]. Potential participants were also excluded if they had epilepsy, a permanent pacemaker, dermatitis or oedema of the affected hand or if they could not give verbal or written consent.

*Stratification and Randomisation*

After giving informed consent, participants were randomised to either the experimental group comprising 45 minutes of RSS delivered daily for 2 weeks via a glove plus usual care (RSS) or usual care (UC) alone, stratified based upon their NIHSS arm score (1-2; 3-4). Group allocations were placed in serially numbered sealed envelopes in two blocks to be opened after consenting.

*Interventions*

The RSS group were provided with an appropriate sized glove and stimulator box (Figure 1). The RSS glove was placed on the affected hand by the participant with aid from a rehabilitation assistant and/or a family member, as required. Supra-sensory pulses were delivered at a frequency of 20 Hz with an intensity of 1 to 20mA by electrodes within each glove positioned on the distal and proximal phalanges, providing stimulation to all fingers. The intensity of the current was increased to the highest level that the participant could tolerate and, once this intensity was reached, the participant received 45 minutes of stimulation. This duration was chosen as 30 minutes of supra-sensory hand stimulation has been shown to increase cortical excitability, which plateaus by 45 minutes [25-27]. RSS was repeated daily for two weeks (14 sessions, total time: 630 minutes)[21].

Usual Care (UC) comprised a range of individually tailored interventions (necessary for the individual patient) delivered by physiotherapists and occupational therapists who were specialised in neurological rehabilitation. The RSS and UC groups were not matched for time and attention but the duration of UC and RSS were noted after each treatment session.

Acceptability was evaluated by sending 21 participants/carers in the RSS group at Chester a postal questionnaire after the completion of the study. The questionnaire was developed specifically for this study and comprised 10 open, free-text questions (see appendix 1). These were completed by the participant and/or their carer and asked about: their perception of the RSS glove, ease of use, positive and negative aspects of using it, whether they felt it helped, if so how, what they did when wearing it, would they recommend it to others and would they use it again in future plus provide any other comments about their experience.

*Measurements*

Demographic data comprising type of stroke (ischaemic or haemorrhagic), pre-stroke and immediate post-stroke function (mRS), stroke severity (NIHSS) was collected on all participants prior to commencement of the study. The primary outcome tool was the Action Research Arm Test (ARAT) assessed by an independent blinded assessor by viewing the video recording of the participants performing completing this test both at two weeks and at the end of three months from the randomisation.[29]

Secondary outcomes included the Fugl-Meyer Assessment of upper extremity outcome tool (FMA-UE) and nine hole peg test (NHPT).[30,31] These outcomes were re-assessed two weeks after starting the intervention and at 3 months follow up by a blinded assessor who viewed video recordings of participants completing the items on each outcome tool.

**Analysis**

Feasibility was evaluated by examining:

* Ease of recruitment expressed as a proportion of enrolled participants/proportion of the screened participants from inpatients on the stroke units
* Adherence of using the RSS glove (expressed as a percentage of the maximum time of 630 minutes if the glove was worn for 45 minutes, every day for 2 weeks). This was collected both manually by asking patients or their family member to complete a daily treatment diary during the treatment period ~~as well as from~~ which was subsequently compared with the data downloaded from the RSS generator, so was not reliant on participant recollection. Reasons for non-adherence were collected, where possible.
* Safety of the intervention over 3 months (including the 2 week intervention period). Several potential adverse events were specifically identified and were:
	+ any damage to the skin integrity of the hand (including ulcers, necrosis) within 30 days of enrolment,
	+ epileptic seizures,
	+ the presence of a painful shoulder on the affected upper limb,
	+ contracture of the affected hand, and
	+ any other adverse events reported by the investigator.

Acceptability was judged from RSS participant’s responses to the postal questionnaire sent after the study had finished.

Changes in primary and secondary outcome measures were examined using descriptive statistics and logistic regression. The changes in scores in RSS and UC groups were compared to published values of minimal clinical important differences (MCID) in acute and chronic stroke. [32-35] A pre-specified set of criteria of “successful outcome” for the primary outcome measure (ARAT) was developed based on the improvement in the ARAT score used by Shaw et al in BoTULS trial.[36] A successful outcome was defined as:

* + >3 points improvement if baseline ARAT score of 0-3.
	+ >6 points improvement if baseline ARAT score of 4-51
	+ An ARAT score of 57 or above if baseline ARAT score was >51

Using these pre-specified criteria of good outcome, a calculation using a 80% power was used to indicate the sample size needed to detect a proportion of good outcomes from 45% to 57.5% with treatment ( α = 0.05, 2-tailed). All data were analysed using IBM SPSS software version 24.

**Results**

**Feasibility**

From 9th of January 2017 to 10th of November 2017 (10 months), 417 people admitted after a stroke were screened and 52 of them were eligible to participate; of which 40 (23 females, four left handed) were included in the trial, giving a recruitment rate of 77% of those eligible to participate. The reasons for exclusions non-recruitment and participant flow through the study are illustrated in Figure 2.

After providing consent, participants were randomised to usual care (UC, n=17) or RSS groups (RSS, n=23). All participants had suffered an ischaemic stroke except one who had a haemorrhagic stroke and was randomised to the RSS group. Twenty eight participants had known hypertension (RSS=16, UC=12), 12 had a history of AF (RSS=5, UC=2) and 5 had survived a previous stroke (RSS=3, UC=2). Seven participants had a stroke affecting their dominant side in the RSS group, with 8 having a stroke on their dominant side in the UC group. Baseline characteristics of participants in the RSS and UC groups are shown in Table 1.

Both groups received over 18 hours of therapy during the intervention but, as groups were not matched for time and attention, the RSS group received somewhat more (combined occupational and physio therapy; RSS median, range: 1305, 70-7095 minutes; UC: 1085; 0-3380 minutes). However, the amount of upper limb specific physiotherapy time was not different between the groups (combined upper limb physiotherapy; RSS median, range: 210, 135-335 minutes; UC: 215; 0-445 minutes).

Adherence to the RSS intervention appeared good. Eleven participants (48%) completed 45 minutes in every session and so received the maximum dose of RSS (630 minutes, 100%) and a further 8 (35%) received over 75% of the maximum dose (over 495 minutes). Only two participants (4%) completed less than 50% of the sessions as they had a carotid surgery (endarterectomy) during the study period. Other reasons for non-completion of all the sessions was machine dysfunction (n=2, 9%), and patients choice (n=6, 26%).

Few adverse events were recorded and were generally mild. Shoulder pain was reported by 8(35%) people in the RSS group and 5(29%) in the UC group. One person in the RSS group reported pain in the web space of their thumb which had been there since having their stroke and was not worsened by the intervention. No participants had any seizures, but one participant in the UC passed away during the study period for reasons considered unconnected to the intervention.

*Acceptability to participants*

Nine participants and/or their carers from the RSS group completed and returned questionnaires (return rate: 43% of 21 participants). Two reported that they found the RSS glove easy to use, 7 found it ‘fiddly’ initially but 6 of these 7 reported that this got easier with practice. Three participants felt the glove had not worked, but 3 participants felt they had more movement in their hand after the intervention. Five participants reported no negative effects after using the glove, 2 felt it was slightly painful and the remaining two respondents reported that it was quite tight with one noting that their skin appeared dry after using it. Five people would recommend the RSS glove to other people who have had a stroke whilst one would not. Two would recommend it if it was shown to be beneficial, whilst one participant stated it was worth trying.

**Outcome**

Changes from baseline to two weeks and three months on the outcome measures used are presented in Table 2. A change in the ARAT scores indicating a successful outcome from baseline was seen for 16 (70%) people in the RSS group and 8 (47%) in the UC group at 2 weeks. At 3 months, this increased in both groups (RSS: 17 people, 74%; UC: 11 people, 69%).

**Table 2: Outcome**

|  |  |  |
| --- | --- | --- |
| Outcome tool | 2 weeks | 3 months |
| RSS | UC | RSS | UC# |
| **Change in ARAT** Median (IQR) Range  | 8 (19)0 – 38 | 3 (16)-9 - 30 | 16 (30)0-51 | 7 (23)0-55 |
| **Change in FMA-UE** Median (IQR) Range  | 12 (15)-1 – 33 | 6 (12)-11 - 22 | 16 (14)-6 – 45 | 11.5 (13)-6 -31 |
| **Change in NHPT\*** Median (IQR) Range | -6.1 (-162)-282 – 17 | 0 (-82)-252 - 26.1 | -55.3 (-163)-269 – 0 | -8.6 (-206)-265 – 11.8 |

# indicates n=16 as 1 participant in the UC group died before 3 months. Positive changes indicate improvement except for NHPT. ARAT – Action Research Arm Test; FMA UE Fugl Meyer Assessment Upper Extremity, NHPT – nine hole peg test\* if participants could not undertake the test, they were scored as taking 300 seconds.

To further quantify the improvement in outcome after using the intervention, logistic regression was used to calculate an odds ratio that showed that after using the glove the patient was over 3 times more likely to reach a good outcome at 2 weeks (OR = 3.27, 95% Confidence interval (0.88, 12.13)) and 1.5 times at three months (OR = 1.55, 95% Confidence interval (0.44, 5.53)). As those in the intervention group had a lower baseline ARAT score, this variable was then added to the model to estimate an adjusted odds ratio. After adjusting for baseline ARAT score those patients who used the glove were still over 3 times more likely to achieve a good outcome at 2 weeks (Adjusted OR = 3.10, 95% confidence interval (0.79, 11.39)) and 1.3 times at three months (Adjusted OR = 1.36, 95% confidence interval 0.37, 5.02)).

The change in median ARAT and FME-UE score in both groups are illustrated in Figures 3 and 4 (for waterfall plots on individual changes in ARAT score please see the supplementary Figure 1A and 1B) In the RSS group, 10 participants (from 23, 44%) had a change exceeding the minimal clinical important difference (MCID, 12 points) in acute stroke[33] compared to 4 people (from 17, 24%) in the UC group exceeded the MCID at 2 weeks. At 3 months, the number of people in the RSS group who exceeded the MCID of 5.7 points on the ARAT for chronic stroke[32] increased to 16 (70%) and to 9 in the UC group (56%).

The FMA-UE scores showed that 13 people in the RSS group exceeded the MCID of 9 points at 2 weeks compared to 4 in the UC group[36, 37]. At three months, 15 people in the RSS group and 9 in the UC group had improved by over 9 points. On the NHPT 10 participants exceeded the minimal detectable change of 33 seconds in the RSS group, compared to 5 in the UC group; these values were unchanged at 3 months.[38]

Based on these results, the sample size needed for a definitive trial of effectiveness of RSS in the acute period after stroke will be 550 participants, including a 10% attrition rate. A trial with 250 patients per group would have 80% power to detect an increase in the proportion of positive clinical outcomes from 45% to 57.5% using the intervention (α = 0.05, 2-tailed).

**Discussion**

This is the first study to examine an RSS intervention in the acute, very early period after stroke and provides important data regarding the feasibility of a trial of RSS and the safety and acceptability of the RSS intervention during this time. The rehabilitation undertaken in the first few days and weeks after stroke is likely to be immensely influential on long-term outcomes[39, 40]. The finding of this study indicate that RSS intervention delivered in the acute and early subacute phases after stroke[20] appears safe and acceptable and may benefit upper limb function when used to augment usual care.

**Feasibility and acceptability**

The first aim of the study was to examine the feasibility of an RSS intervention during the early acute period after stroke. The majority of inpatients after stroke did not conform to the inclusion criteria (n=365) or declined to participate (n=10) resulting in a recruitment rate of 11%. The largest number of potential participants were excluded as they had no or very mild arm involvement after stroke and/or had significant functional restrictions prior to having their stroke. Other trials using forms of RSS have reported some challenges in recruiting suitable participants.[21] This may have been exacerbated in the current study as participants were approached in the first days after stroke and so may have been more likely to decline to participate whilst others were unable to clearly give informed consent due to cognitive or communication problems (n=37). These findings indicate that for a future trial of RSS, a multi centred design will be required to ensure the study is adequately powered and that different formats of presenting information and gaining consent for those with communication difficulties and/or cognitive problems should be considered to broaden inclusion.

Once recruited to the study, adherence to the use of the RSS glove was good with 19 from 23 participants completing over 75% of the entire treatment dose. There were few adverse events and those that were reported were relatively minor (dry skin, shoulder discomfort). There were no drop outs from the RSS group, suggesting that the intervention was well tolerated. From those that returned the questionnaire, participants found the glove relatively easy to use after practice and familiarisation and most reported benefit. These findings agree with other reports of RSS in subacute stroke [21] and indicate that RSS may be an attractive treatment for people early after stroke but are limited as a standardised tool to quantify acceptability was not used, and it is not known why less than half of those asked returned their questionnaires and hence this part of the result should be interpreted with some caution.

**Changes after the intervention**

The ARAT, FMA-UE and 9HPT all indicated somewhat greater improvement in the RSS group when compared to the UC group, with benefits exceeding the MCID for the majority of RSS participants on the ARAT and FMA-UE. Improvements on all outcomes were most marked immediately after the intervention period and the rate of improvement appeared to attenuate after the intervention had ceased. This might indicate that an intervention period longer than two weeks used in the current study might elicit even greater improvements. Few have used an intervention period of more than 2 weeks when evaluating RSS. Peurala et al. (2002) applied RSS twice a day for three weeks in 59 people with chronic stroke; Conforto et al., (2010) used it for three times a week for 1 month in 22 people with subacute and chronic stroke whilst participants in Smith et al.’s (2009) study received 9 minutes of sensory stimulation four times a week for six weeks. [15, 18, 42] Whilst all reported some improvements in upper limb function, none used similar outcome measures either to each other or to the current study, making direct conclusions about the effects of dose impossible. This indicates that future studies should consider the effect of dose on response to inform the clinical use of RSS.

**Limitations**

A key limitation of this study was that the RSS and UC groups were not matched for time and attention and so the differences between groups may be simply attributable to a greater intervention dose in the RSS group, irrespective of the intervention content. The RSS group received over 165 minutes more treatment (RSS and usual care) than the UC group during the intervention period and the treatment received after the intervention had finished was not standardised nor monitored in either group. Others have shown that more intensive treatments can elicit greater improvements in upper limb function[42] and it has been suggested that this may be independent of the content of the intervention to some degree.[40] In their randomised controlled trial of RSS in the acute/sub-acute period after stroke, Kattenstroth et al. (2018) included a time-matched control intervention (sham) and found that there were very few significant differences between groups on individual outcome measures, including the NHPT used in the current study.[21] This highlights inclusion of an appropriate sham treatment is vital in a future trial of RSS to ensure treatment times and expectations of benefit are as closely matched as possible so that the presence and magnitude of any effect of RSS can be clearly identified.

Another limitation of the current study was that the groups were not fully equivalent at baseline. The RSS group was randomised to start their treatment two days earlier than the UC group, and the RSS group had slightly better function prior to their stroke (median pre-stroke mRS scores, IQR: RSS= 1, 2; UC=2, 2) and marginally better stroke status (median NIHSS scores, IQR: RSS:6, 5; UC:7, 7). However, despite stratification on NIHSS arm scores the RSS group demonstrated poorer arm function at baseline (ARAT FMA-UE), suggesting that the NIHSS arm score may not be sensitive or suitable to stratify groups in a definitive trial. Other tools which could be used to stratify groups to ensure equality in a future trial include the SAFE score and/or PREP2 algorithm.[44,45] These tools have shown an ability to predict the recovery of arm function in 75% of people after stroke but are complicated by their need to use transcranial magnetic stimulation, which may not be available in some clinical settings.[45]

Despite potential practical limitations, exploration of sensorimotor cortical function does have an important role in providing an understanding of the mechanisms by which RSS may elicit changes in upper limb function after stroke. Some have reported specific reductions in GABA-ergically mediated intra-cortical inhibition in the motor cortex which can be present even after a single 2 hour RSS session in people with chronic stroke (n=9) [46] whilst others have found that a longer 4 week duration of thrice weekly RSS in people with chronic stroke did not significantly alter corticomotor excitability from baseline.[18] These findings are supported by others [19] and indicate that the primary mechanism of RSS is likely to be potentiation via glutamatergic connections between the primary sensory and motor cortices, rather than alterations in intra-cortical excitability.[14] However, further research is needed to inform an ‘optimum’ dose of RSS to benefit motor function after stroke as inconsistencies in the data mean that there is little evidence on which to base current treatment parameters.

**Conclusions**

The results from this single blinded randomised controlled feasibility study show that RSS is acceptable to use in the early acute period after stroke and that recruitment to a trial to determine its effectiveness is feasible but is likely to require a multi-centre design. This is the first study of RSS in the acute period after stroke and showed that an RSS intervention was well-tolerated and that participants were largely adherent to the daily RSS programme over two weeks. The differences between groups at baseline suggest that a definitive trial of the effectiveness of RSS for people in the early period after stroke should consider using a more sensitive measure of arm function and/or a prognostic indicator to stratify groups to ensure equality. The RSS intervention appeared to elicit larger improvements during the intervention period than usual care alone, but groups were not matched for time and attention. Therefore, a future trial should include a credible control intervention, such as a sham glove. The differences between the measures of upper limb function between the UC and RSS groups were most marked during the intervention and were attenuated at 3 months. Whilst many studies have used a shorter intervention period than the current work, these findings suggest that further research is necessary to determine if a longer or more intensive programme of RSS could elicit larger changes in upper limb function than those seen here and to elucidate the mechanism by which RSS may improve sensorimotor function.

**Table 1 Baseline characteristics of participants in the RSS and UC groups**

|  |  |  |
| --- | --- | --- |
|  | RSS + Usual Care (n=23) | Usual Care (n=17) |
| Time from Stroke to Randomisation (days) median (IQR) Range | 4 (3)2-11 | 6 (8)2-14 |
| NIHSS Arm score median (IQR) Range | 1 (3)1-4 | 2 (3)1-4 |
| Dominant hand Left Right | 1 (4.3%)22 (95.7%) | 3 (17.6%)14 (62.4%) |
| NHSS Arm group 1-2 3-4 | 16 (69.6%)7 (30.4%) | 11 (64.7%)6 (35.3%) |
| Age Median (IQR) Range | 72.09 (15)37-90 | 77.15 (21)53-92 |
| Gender Female Male | 12 (52.2%)11 (47.8%) | 11 (64.7%)6 (35.3%) |
| Pre stroke Rankin score Median (IQR) Range | 1 (2)0-3 | 2 (2)0-3 |
| Total NIHSS Score Median (IQR) Range | 6 (5)2-17 | 7 (7)2-27 |
| FMA-UE Median (IQR) Range | 95 (46)43-118 | 104 (34)36-117 |
| FMA-UE (Section H: Sensation) Median (IQR)(Maximum score:12) Range | 10 (4)0-12 | 11 (5.5)0-12 |
| ARAT Median (IQR) Range | 26 (47)0-57 | 39 (54)0-57 |
| NHPT Time (s) Median (IQR) Range | 300 (151)29-300 | 300 (259)27-300 |

NIHSS – National Institute of Health Stroke Scale, FMA-UE- Fugl Meyer Assessment Upper Extremity, ARAT – Action Research Arm Test, NHPT – Nine Hole Peg Test, if participants could not undertake the test, they were scored as taking 300 seconds (maximum time allocated before terminating the test).

**List of abbreviations**

ADLs: Activities of Daily Living

ARAT: Action Research Arm Test

FMA-UE: Fugl-Meyer Assessment of upper extremity

MCID: minimal clinical important differences

mRS: modified Rankin scale

NIHSS: National Institute of Health Stroke Scale

NHPT: nine hole peg test

OR: odds ratio

RSS: repetitive sensory stimulation

RTT: repetitive task training

UC: usual care

## Declarations

***Ethics approval and consent to participate***

Ethical approval was obtained from North West-Liverpool Central Research Ethics Committee (ref no: 16/NW/07/71; IRAS ID: 215137) and Health Research Authority (HRA) prior to the commencement of the trial. A written consented was obtained from all participants by a GCP trained researcher, prior to enrolment and randomisation. This study was performed in compliance with the Helsinki Declaration.

***Consent for publication***

Not Applicable.

***Availability of data and material***

All data analysed during this study are included in this published article (as a supplementary information files).

***Competing interests***

Nothing to declare.

***Funding***

The trial was sponsored by the Countess of Chester Hospital NHS Foundation Trust and was funded by the BHR PHARMACEUTICAL LTD who supplied the Tipstim gloves and training and funded the trial cost to the Countess of Chester Hospital NHS Foundation Trust, but did not have any access to the trial material.

***Authors' contributions***

Kausik Chatterjee: Acted as a Chief Investigator and made a substantial contribution for the design, analysis and interpretation of data and been involved in drafting the manuscript and revising it critically for important intellectual content.

Rachel C Stockley: Is involved in drafting the manuscript and revising it critically for important intellectual content.

Steven Lane: Has made a substantial contribution analysis and interpretation of data and been involved in critically revising the manuscript for important intellectual content.

Caroline Watkins: Is involved in and critically revising the manuscript for important intellectual content.

Katy Cottrell: Acted as a co-investigator and made a substantial contribution for the design, acquisition of data and been involved in revising the manuscript critically for important intellectual content.

Brenda Ankers: Has made a substantial contribution for running the trial at the multiple sites and in the acquisition of data.

Sioned Davies: Has acted as a blind assessor and made a substantial contribution in the acquisition of data.

Mary Fisher Morris: Acted as a trial manager and made a substantial contribution for the design and been involved in drafting the manuscript and revising it critically for important intellectual content.

Nick Fallon: Is involved in critically revising the manuscript for important intellectual content.

Turo Nurmikko: Is involved in critically revising the manuscript for important intellectual content.

All authors read and approved the final manuscript.

***Acknowledgements***

 Jasvir Deol, Jessica Langley and the therapy team at the Basildon and Thurrock Hospital NHS Foundation Trust Stroke Therapy team.

Reference list

1. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383(9913):245-54. PubMed PMID: 24449944; PubMed Central PMCID: PMCPMC4181600.

2. Patel AB, V; King, D; Quayyum, Z; Wittenberg, R; Knapp, M. Executive summary Part 2: Burden of Stroke in the next 20 years and potential returns from increased spending on research. London: Stroke Association, 2017.

3. Xu X-M, Vestesson E, Paley L, Desikan A, Wonderling D, Hoffman A, et al. The economic burden of stroke care in England, Wales and Northen Ireland: Using a national stroke register to estimate and report patient-level health economic outcomes in stroke. European Stroke Journal. 2018;3(1):82-91.

4. Chen CM, Tsai CC, Chung CY, Chen CL, Wu KP, Chen HC. Potential predictors for health-related quality of life in stroke patients undergoing inpatient rehabilitation. Health and quality of life outcomes. 2015;13:118. Epub 2015/08/06. doi: 10.1186/s12955-015-0314-5. PubMed PMID: 26243294; PubMed Central PMCID: PMCPMC4524441.

5. Broeks JG, Lankhorst GJ, Rumping K, Prevo AJ. The long-term outcome of arm function after stroke: results of a follow-up study. Disabil Rehabil. 1999;21(8):357-64. PubMed PMID: 10503976.

6. Morris JH, van Wijck F, Joice S, Donaghy M. Predicting health related quality of life 6 months after stroke: the role of anxiety and upper limb dysfunction. Disabil Rehabil. 2013;35(4):291-9. Epub 2012/06/14. doi: 10.3109/09638288.2012.691942. PubMed PMID: 22691224.

7. Poltawski L, Allison R, Briscoe S, Freeman J, Kilbride C, Neal D, et al. Assessing the impact of upper limb disability following stroke: a qualitative enquiry using internet-based personal accounts of stroke survivors. Disabil Rehabil. 2016;38(10):945-51. doi: 10.3109/09638288.2015.1068383. PubMed PMID: 26200448; PubMed Central PMCID: PMCPMC4819828.

8. Langhorne P, Legg L. Evidence behind stroke rehabilitation. J Neurol Neurosurg Psychiatry. 2003;74 Suppl 4:iv18-iv21. PubMed PMID: 14645462; PubMed Central PMCID: PMCPMC1765642.

9. French B, Thomas LH, Coupe J, McMahon NE, Connell L, Harrison J, et al. Repetitive task training for improving functional ability after stroke. Cochrane Database Syst Rev. 2016;11:CD006073. doi: 10.1002/14651858.CD006073.pub3. PubMed PMID: 27841442.

10. Cortes JC, Goldsmith J, Harran MD, Xu J, Kim N, Schambra HM, et al. A Short and Distinct Time Window for Recovery of Arm Motor Control Early After Stroke Revealed With a Global Measure of Trajectory Kinematics. Neurorehabil Neural Repair. 2017;31(6):552-60. doi: 10.1177/1545968317697034. PubMed PMID: 28506149; PubMed Central PMCID: PMCPMC5434710.

11. Party ISW. Sentinel Stroke National Audit Programme. 2017.

12. Hayward KS, Brauer SG. Dose of arm activity training during acute and subacute rehabilitation post stroke: a systematic review of the literature. Clin Rehabil. 2015;29(12):1234-43. doi: 10.1177/0269215514565395. PubMed PMID: 25568073.

13. Beste C, Dinse HR. Learning without training. Curr Biol. 2013;23(11):R489-99. doi: 10.1016/j.cub.2013.04.044. PubMed PMID: 23743417.

14. Veldman MP, Maffiuletti NA, Hallett M, Zijdewind I, Hortobagyi T. Direct and crossed effects of somatosensory stimulation on neuronal excitability and motor performance in humans. Neurosci Biobehav Rev. 2014;47:22-35. doi: 10.1016/j.neubiorev.2014.07.013. PubMed PMID: 25064816.

15. Smith PS, Dinse HR, Kalisch T, Johnson M, Walker-Batson D. Effects of repetitive electrical stimulation to treat sensory loss in persons poststroke. Archives of Physical Medicine & Rehabilitation. 2009;90(12):2108-11. doi: <https://dx.doi.org/10.1016/j.apmr.2009.07.017>. PubMed PMID: 19969176.

16. Sullivan JE, Hedman LD. Effects of home-based sensory and motor amplitude electrical stimulation on arm dysfunction in chronic stroke. Clinical Rehabilitation. 2007;21(2):142-50. PubMed PMID: 0095835.

17. Wu CW, Seo H, Cohen LG. Influence of electric somatosensory stimulation on paretic-hand function in chronic stroke. Archives of Physical Medicine & Rehabilitation. 2006;87(3):351-7. PubMed PMID: 106146613. Language: English. Entry Date: 20070907. Revision Date: 20150711. Publication Type: Journal Article.

18. Conforto AB, Ferreiro KN, Tomasi C, dos Santos RL, Moreira VL, Marie SK, et al. Effects of somatosensory stimulation on motor function after subacute stroke. Neurorehabil Neural Repair. 2010;24(3):263-72. doi: 10.1177/1545968309349946. PubMed PMID: 19884642; PubMed Central PMCID: PMCPMC2824782.

19. Conforto AB, Santos RL, Farias SN, Marie SK, Mangini N, Cohen LG. Effects of somatosensory stimulation on the excitability of the unaffected hemisphere in chronic stroke patients. Clinics (Sao Paulo). 2008;63(6):735-40. PubMed PMID: 19060993; PubMed Central PMCID: PMCPMC2664271.

20. Bernhardt J, Hayward KS, Kwakkel G, Ward NS, Wolf SL, Borschmann K, et al. Agreed Definitions and a Shared Vision for New Standards in Stroke Recovery Research: The Stroke Recovery and Rehabilitation Roundtable Taskforce. Neurorehabil Neural Repair. 2017;31(9):793-9. doi: 10.1177/1545968317732668. PubMed PMID: 28934920.

21. Kattenstroth JC, Kalisch T, Sczesny-Kaiser M, Greulich W, Tegenthoff M, Dinse HR. Daily repetitive sensory stimulation of the paretic hand for the treatment of sensorimotor deficits in patients with subacute stroke: RESET, a randomized, sham-controlled trial. BMC Neurology. 2018;18:1-13. doi: 10.1186/s12883-017-1006-z. PubMed PMID: 127291980. Language: English. Entry Date: In Process. Revision Date: 20180623. Publication Type: journal article. Journal Subset: Biomedical.

22. Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol. 2006;5(7):603-12.

23. Goldstein, L. B., Bertels, C. and Davis, J. N. (1989). “Interrater reliability of the NIHSS stroke scale.” Arch Neurol 46: 660-662.

24. Dromerick AW, Edwards DF, Diringer MN. Sensitivity to changes in disability after stroke: a comparison of four scales useful in clinical trials. JRehabil Res Dev. 2003;40(1):1-8.

25. Rankin J. Cerebral vascular accidents in patients over 60. Scottish Medical Journal. 1957;2:200-15.

26. Golaszewski SM, Bergmann J, Christova M, Kunz AB, Kronbichler M, Rafolt D, et al. Modulation of motor cortex excitability by different levels of whole-hand afferent electrical stimulation. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2012;123(1):193-9. doi: 10.1016/j.clinph.2011.06.010. PubMed PMID: 21764634.

27. Golaszewski SM, Siedentopf CM, Koppelstaetter F, Rhomberg P, Guendisch GM, Schlager A, et al. Modulatory effects on human sensorimotor cortex by whole-hand afferent electrical stimulation. Neurology. 2004;62(12):2262-9. PubMed PMID: 15210892.

28. McKay D, Brooker R, Giacomin P, Ridding M, Miles T. Time course of induction of increased human motor cortex excitability by nerve stimulation. Neuroreport. 2002;13(10):1271-3. PubMed PMID: 12151785.

29. Lyle RC. A performance test for assessment of upper limb function in physical rehabilitation treatment and research. IntJRehabilRes. 1981;4(4):483-92.

30. Singer B, Garcia-Vega J. The Fugl-Meyer Upper Extremity Scale. J Physiother. 2017;63(1):53. doi: 10.1016/j.jphys.2016.08.010. PubMed PMID: 27964964.

31. Mathiowetz V, Weber K, Kashman N, Voliand G. Adult Norms for the nine hole peg test of dexterity. Occ Ther J Res. 1985;5:24-38.

32. Van der Lee JH, De Groot V, Beckerman H, Wagenaar RC, Lankhorst GJ, Bouter LM. The intra- and interrater reliability of the action research arm test: a practical test of upper extremity function in patients with stroke. Arch Phys Med Rehabil. 2001;82(1):14-9. Epub 2001/03/10. doi: 10.1053/apmr.2001.18668. PubMed PMID: 11239280.

33. van der Lee JH, Beckerman H, Lankhorst GJ, Bouter LM. The responsiveness of the Action Research Arm test and the Fugl-Meyer Assessment scale in chronic stroke patients. J Rehabil Med. 2001;33(3):110-3. Epub 2001/08/03. PubMed PMID: 11482350.

34. Lang CE, Edwards DF, Birkenmeier RL, Dromerick AW. Estimating minimal clinically important differences of upper-extremity measures early after stroke. Arch Phys Med Rehabil. 2008;89(9):1693-700. Epub 2008/09/02. doi: 10.1016/j.apmr.2008.02.022. PubMed PMID: 18760153; PubMed Central PMCID: PMCPMC2819021.

35. Page SJ, Levine P, Hade E. Psychometric properties and administration of the wrist/hand subscales of the Fugl-Meyer Assessment in minimally impaired upper extremity hemiparesis in stroke. Arch Phys Med Rehabil. 2012;93(12):2373-6.e5. Epub 2012/07/05. doi: 10.1016/j.apmr.2012.06.017. PubMed PMID: 22759831; PubMed Central PMCID: PMCPMC3494780.

36. Shaw L, Rodgers H, Price C, van Wijck F, Shackley P, Steen N, et al. BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health technology assessment (Winchester, England). 2010;14(26):1-113, iii-iv. Epub 2010/06/03. doi: 10.3310/hta14260. PubMed PMID: 20515600.

37. Shelton FD, Volpe BT, Reding M. Motor impairment as a predictor of functional recovery and guide to rehabilitation treatment after stroke. Neurorehabil Neural Repair. 2001;15(3):229-37. Epub 2002/04/12. doi: 10.1177/154596830101500311. PubMed PMID: 11944745.

38. Arya KN, Verma R, Garg RK. Estimating the minimal clinically important difference of an upper extremity recovery measure in subacute stroke patients. Top Stroke Rehabil. 2011;18 Suppl 1:599-610. Epub 2011/11/29. doi: 10.1310/tsr18s01-599. PubMed PMID: 22120029.

39. Chen HM, Chen CC, Hsueh IP, Huang SL, Hsieh CL. Test-retest reproducibility and smallest real difference of 5 hand function tests in patients with stroke. Neurorehabil Neural Repair. 2009;23(5):435-40. Epub 2009/03/06. doi: 10.1177/1545968308331146. PubMed PMID: 19261767.

40. Krakauer JWC, S.T. Broken Movement: MIT Press; 2017.

41. Krakauer JW, Carmichael ST, Corbett D, Wittenberg GF. Getting neurorehabilitation right: what can be learned from animal models? Neurorehabil Neural Repair. 2012;26(8):923-31. Epub 2012/04/03. doi: 10.1177/1545968312440745. PubMed PMID: 22466792; PubMed Central PMCID: PMCPMC4554531.

42. Peurala SH, Pitkanen K, Sivenius J, Tarkka IM. Cutaneous electrical stimulation may enhance sensorimotor recovery in chronic stroke. Clin Rehabil. 2002;16(7):709-16. doi: 10.1191/0269215502cr543oa. PubMed PMID: 12428819.

43. McCabe J, Monkiewicz M, Holcomb J, Pundik S, Daly JJ. Comparison of robotics, functional electrical stimulation, and motor learning methods for treatment of persistent upper extremity dysfunction after stroke: a randomized controlled trial. Arch Phys Med Rehabil. 2015;96(6):981-90. doi: 10.1016/j.apmr.2014.10.022. PubMed PMID: 25461822.

44. Stinear CM, Barber PA, Petoe M, Anwar S, Byblow WD. The PREP algorithm predicts potential for upper limb recovery after stroke. Brain. 2012;135(Pt 8):2527-35. doi: 10.1093/brain/aws146. PubMed PMID: 22689909.

45. Stinear CM, Byblow WD, Ackerley SJ, Smith MC, Borges VM, Barber PA. PREP2: A biomarker-based algorithm for predicting upper limb function after stroke. Ann Clin Transl Neurol. 2017;4(11):811-20. doi: 10.1002/acn3.488. PubMed PMID: 29159193; PubMed Central PMCID: PMCPMC5682112.

46. Celnik P, Hummel F, Harris-Love M, Wolk R, Cohen LG. Somatosensory stimulation enhances the effects of training functional hand tasks in patients with chronic stroke. Archives of Physical Medicine & Rehabilitation. 2007;88(11):1369-76. PubMed PMID: 105843292. Language: English. Entry Date: 20080314. Revision Date: 20150711. Publication Type: Journal Article.